AFT Pharmaceuticals - Poised for international market expansion
AFT continues to focus on expanding its product portfolio and broadening its geographical footprint (including increased investments in its...
282 Views
AFT Pharmaceuticals - US milestone triggers upside and guidance bump
AFT Pharmaceuticals has announced the first sale of its intravenous pain relief medicine, Maxigesic IV, through its US licensing partner, Hikma...
310 Views
AFT Pharmaceuticals - A Bumpy Road
While it stated this was due to weaker-than-expected Australasian sales, relative to our expectations it was gross margins remaining soft.
180 Views
AFT Pharmaceuticals - US maiden voyage with Maxigesic IV launch
AFT Pharmaceuticals has announced the launch of Maxigesic IV, an intravenous form of its flagship pain relief prescription medicine, in the US...
186 Views
AFT Pharmaceuticals - Another R&D asset in the bag
AFT Pharmaceuticals has announced the addition of another candidate, HY-091, to its R&D pipeline, for the management of vulvar lichen sclerosus...
202 Views